Specifically, CHARLS’repeated AIP measurements allow us to calculate CumAIP (time-weighted cumulative AIP exposure), while its detailed demographic and clinical data enable rigorous adjustment for confounders (e.g., metabolic disorders, vascular pathologies) that could obscure the CumAIP–dementia association. This evidence concerns the gene AIP and Other metabolic disease.